Non-invasive bioluminescence imaging to monitor the immunological control of a plasmablastic lymphoma-like B cell neoplasia after hematopoietic cell transplantation

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Chopra, Martin ^a,b   Kraus, Sabrina ^a,b   Schwinn, Stefanie ^a,b   Ritz, Miriam ^a,b   Mattenheimer, Katharina ^a,b   Mottok, Anja ^b   Rosenwald, Andreas ^b   Einsele, Hermann ^a   Beilhack, Andreas ^a,b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; FIREFLY LUCIFERASE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL CULTURE; B CELL LYMPHOMA; BIOLUMINESCENCE; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE TRANSLOCATION; GRAFT VERSUS LEUKEMIA EFFECT; IM380 CELL LINE; IMMUNOLOGICAL MONITORING; METASTASIS; MOUSE; NEOPLASM; NON INVASIVE PROCEDURE; NONHUMAN; ONCOGENE C MYC; PLASMABLASTIC LYMPHOMA LIKE B CELL NEOPLASIA; PROTEIN EXPRESSION; RADIOSENSITIVITY; SPLEEN CELL; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR MODEL;

ANIMALS; B-LYMPHOCYTES; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LUMINESCENT MEASUREMENTS; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TRANSPLANTATION, HOMOLOGOUS;

EID: 84892532073     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081320     Document Type: Article

References (36)

1. Cheon DJ, Orsulic S (2011) Mouse models of cancer. Annu Rev Pathol 6: 95-119.
2. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, et al. (1982) Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U.S.A 79: 7824-7827.
3. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, et al. (1982) Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U.S.A 79: 7837-7841.
4. Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, et al. (2000) Burkitt lymphoma in the mouse. J Exp Med 192:1183-1190.
5. Blum KA, Lozanski G, Byrd JC (2004) Adult Burkitt leukemia and lymphoma. Blood 104: 3009-3020.
6. Navid F, Mosijczuk AD, Head DR, Borowitz MJ, Carroll AJ, et al. (1999) Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: the Pediatric Oncology Group experience. Leukemia 13: 135-141.
7. Mussolin L, Pillon M, Conter V, Piglione M, Lo Nigro L, et al. (2007) Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood. J Clin Oncol 25: 5254-5261.
8. Gould J, Alexanian R, Goodcare A, Pathak S, Hecht B, et al. (1988) Plasma cell karyotype in multiple myeloma. Blood 71: 453-456.
9. Dib A, Gabrea A, Glebov OK, Bergsagel PL, Kuehl WM (2008) Characterization of MYC translocations in multiple myeloma cell lines. JNCI Monographs 39: 25-31.
10. Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, et al. (2005) Insertion of c-myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res 65: 1306-1315.
11. Contag CH, Jenkins D, Contag PR, Negrin RS (2000) Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia 2: 41-52.
12. Choy G, O'Connor S, Diehn FE, Costouros N, Alexander HR, et al. (2003) Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. BioTechniques 35: 1022-1030.
13. Kim J-B, Urban K, Cochran E, Lee S, Ang A, et al. (2010) Non-invasive detection of a small number of bioluminescent cancer cells in vivo. PLOS ONE 5: e9364.
14. Ross DD, Joneckis CC, Ordóñez JV, Sisk AM, Wu RK, et al. (1989) Estimation of cell survival by flow cytometric quantification of fluorescein diacetate/propidium iodide viable cell number. Cancer Res 49: 3776-3782.
15. Beilhack A, Schulz S, Baker J, Beilhack GF, Wieland CB, et al. (2005) In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 106: 1113-1122.
16. Chopra M, Riedel SS, Biehl M, Krieger S, von Krosigk V, et al. (2013) Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis. Carcinogenesis 34: 1296-1303.
17. Ferry JA (2006) Burkitt's lymphoma: clinicopathologic features and differential diagnosis. Oncologist 11: 375-383.
18. Teruya-Feldstein J, Chiao E, Filippa DA, Lin O, Comenzo R, et al. (2004) CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Ann Oncol 15: 1673-1679.
19. Zuo Z, Tang Y, Bi CF, Zhang WY, Zhao S, et al. (2011) Extraosseous (extramedullary) plasmacytomas: a clinicopathologic and immunophenotypic study of 32 Chinese cases. Diagn Pathol 6:123.
20. Chuang SS, Ye H, Du MQ, Lu CL, Dogan A, et al. (2007) Histopathology and immunohistochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starrysky pattern. A comparative study with EBER and FISH. Am J Clin Pathol 128: 558-564.
21. Kelemen K, Braziel RM, Gatter K, Bakke TC, Olson S, et al. (2010) Immunophenotypic variations of Burkitt lymphoma. Am J Clin Pathol 134: 127-138.
22. Gaur S, Padilla O, Nahleh Z (2013) Clinical features and prognosis of CD20 negative aggressive B-cell non-Hodgkins lymphoma. Lymphoma: 290585
23. Frost M, Newell J, Lones MA, Tripp SR, Cairo MS, et al. (2004) Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol 121: 384-392.
24. O'Connell FP, Pinkus JL, Pinkus GS (2004) CD138 (Syndecan-1), a plasma cell marker. Am J Clin Pathol 121: 254-263.
25. McClure RF, Remstein ED, Macon WR, Dewald GW, Habermann TM, et al. (2005) Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol 29: 1652-1660.
26. Attarbaschi A, Mann G, Schumich A, König M, Pickl WF, et al. (2007) CD44 deficiency is a consistent finding in childhood Burkitt's lymphoma and leukemia. Leukemia 21: 1110-1113.
27. Schniederjan SD, Li S, Saxe DF, Lechowicz MJ, Lee KL, et al. (2010) A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell. Am J Clin Pathol 133: 718-726.
28. Lin P, Jones D, Dorfman DM, Medeiros LJ (2000) Precursor B-cell lymphoblastic lymphoma: a predominantly extranodal tumor with low propensity for leukemic involvement. Am J Surg Pathol 24: 1480-1490.
29. Cortelazzo S, Ponzoni M, Ferreri AJ, Hoelzer D (2011) Lymphoblastic lymphoma. Crit Rev Oncol Hematol 79: 330-343.
30. God JM, Haque A (2011) Immune evasion by B-cell lymphoma. J Clin Cell Immunol: e103.
31. Prochazka V, Jarosova M, Prouzova Z, Nedomova R, Papajik T, et al. (2012) Immune escape mechanisms in diffuse large B-cell lymphoma. ISRN Immunology: 208903.
32. Mori S, Rempel RE, Chang JT, Yao G, Lagoo AS, et al. (2008) Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma. Cancer Res 68: 8525-8534.
33. Niitsu N (2010) Current treatment strategy of diffuse large B-cell lymphomas. Int J Hematol 92: 231-237.
34. Cultrera JL, Dalia SM (2012) Diffuse large B-cell lymphoma: current strategies and future directions. Cancer Control 19: 204-213.
35. Donnou S, Galand C, Touitou V, Sautès-Fridman C, Fabry Z, et al. (2012) Murine models of B-cell lymphomas: promising tools for designing cancer therapies. Adv Hematol 701704.
36. Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481: 306-313.